# Zomedica Corp. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Zomedica Corp.). ## Overview Zomedica Corp. is a U.S.-based veterinary health company that develops and commercializes diagnostic and therapeutic products for companion animals. Its portfolio includes the TRUFORMA, PulseVet, Assisi, TRUVIEW, VetGuardian, and VETIGEL product lines, sold through direct and indirect channels in the United States and international markets. ## Products & services • TRUFORMA veterinary diagnostic platform and assays • PulseVet therapeutic shock wave systems and consumables • Assisi therapeutic devices and consumables • VetGuardian monitoring systems and service agreements • TRUVIEW products, subscriptions, and services • VETIGEL hemostatic consumables - **Diagnostic platforms** (25%) — Veterinary diagnostic instruments and assays used in clinic settings, including TRUFORMA. - **Therapeutic devices** (45%) — Non-invasive veterinary treatment systems and related consumables, including PulseVet and Assisi. - **Monitoring and connected care** (10%) — Remote monitoring hardware, subscriptions, and service agreements for animal care. - **Consumables and disposables** (15%) — Recurring consumable products sold alongside installed platforms and devices. - **Contract manufacturing and engineering** (5%) — Engineering and manufacturing-related revenue recognized from third-party work. - TRUFORMA veterinary diagnostic platform and assays - PulseVet therapeutic shock wave systems and consumables - Assisi therapeutic devices and consumables - VetGuardian monitoring systems and service agreements - TRUVIEW products, subscriptions, and services - VETIGEL hemostatic consumables ## Customers Zomedica sells primarily to veterinary clinics, hospitals, and animal health practitioners that need diagnostic, therapeutic, and monitoring tools for companion animals. Its installed-base model means customers often buy capital equipment first and then purchase recurring consumables, assays, subscriptions, or service agreements over time. - **Veterinary clinics** (primary) — Buy TRUFORMA, PulseVet, Assisi, and related consumables to perform diagnostics and treatments in-house. - **Veterinary hospitals and specialty practices** (primary) — Use therapeutic and monitoring products for broader case mix and higher-acuity animal care. - **Companion animal practitioners** (secondary) — Purchase devices and consumables to support routine and recurring patient care. - **International distributors and channel partners** (secondary) — Buy or place products for resale and local market access outside the U.S. - **Contract manufacturing customers** (emerging) — Purchase engineering and manufacturing services when Zomedica performs third-party work. - Veterinary clinics buying diagnostic tools for in-house testing - Animal hospitals using therapeutic systems for treatment workflows - Practitioners purchasing consumables tied to installed platforms - Customers subscribing to monitoring or service agreements - Clinics adopting products to expand in-clinic capabilities ## Geography Zomedica is headquartered in the United States and reports revenue from both U.S. and international markets. The company also has subsidiaries in Switzerland and Canada, but its functional currency is the U.S. dollar, and its commercial footprint is centered on veterinary customers in North America with additional international sales. - United States is the core market for product sales and services - International revenue comes from select product lines and channels - Switzerland and Canada are operating subsidiaries, not core revenue hubs - U.S. dollar is the reporting currency and functional currency - Geographic mix matters because installed-base sales depend on local adoption ## Strategy Zomedica’s strategy centers on expanding its installed base of veterinary platforms and increasing recurring revenue from consumables, assays, and services. It also emphasizes new assay development for TRUFORMA, broader commercialization of existing products, and selective business development that can add products, capabilities, or manufacturing revenue. - **Grow recurring revenue from installed platforms** (short-term) — The model depends on repeat consumables, assays, and services after device placement. - **Expand TRUFORMA assay menu** (medium-term) — More assays increase platform utility and support customer adoption and utilization. - **Broaden commercialization across product lines** (short-term) — Selling more products across the portfolio reduces dependence on any single platform. - **Pursue selective business development** (medium-term) — Acquisitions or partnerships can add technology, products, or manufacturing capability. - Expand installed base to drive recurring consumables demand - Launch new TRUFORMA assays to broaden diagnostic utility - Grow PulseVet and Assisi consumables through existing customers - Commercialize VETIGEL and other newer product lines - Use business development to add products or capabilities ## Risks Zomedica’s business depends on successful product adoption, customer retention, and continued consumable usage after device placement, so demand weakness or customer churn can quickly reduce recurring revenue. The company also faces impairment risk on goodwill, intangibles, and equipment, plus typical medtech risks around product development, commercialization, and regulatory execution. - **Customer return and churn risk on placed capital** [high] — TRUFORMA-related capital is placed with customers who can return it, which can stop recurring consumable purchases. - **Impairment of goodwill, intangibles, and equipment** [high] — Management disclosed sensitivity to assumptions, discount rates, and market conditions that can trigger write-downs. - **Commercialization and adoption risk** [medium] — New assays, VETIGEL, and other products must gain traction to support growth. - **Funding and dilution risk** [medium] — Future capital needs could require equity issuance or debt, affecting ownership and flexibility. - **Regulatory and product development risk** [medium] — Veterinary diagnostics and therapeutics require ongoing development, validation, and market acceptance. - Installed capital can be returned, reducing future consumable revenue - Revenue depends on adoption of new assays and product launches - Goodwill and intangible assets are exposed to impairment charges - Customer concentration in veterinary channels can slow scaling - Clinical and commercialization execution risk affects product uptake - Additional financing could dilute shareholders if needed ## Accounting The most important accounting judgments are revenue recognition for bundled device, consumable, subscription, and service arrangements, and the valuation of placed capital tied to future consumable purchases. Investors should also watch goodwill and intangible asset impairment, because management uses discounted cash flow and market-based methods that are highly sensitive to assumptions. - **Revenue recognition across multiple product types** — Can shift revenue between periods and affect comparability - **Valuation and payback of placed capital** — Affects asset carrying values and potential write-downs - **Goodwill and intangible asset impairment** — Can produce material non-cash impairment charges - **Property and equipment recoverability** — May require impairment if utilization or placements disappoint - Revenue timing varies across devices, consumables, subscriptions, and services - Placed capital valuation depends on future consumable usage and payback - Goodwill impairment can create large non-cash charges when assumptions weaken - Intangible asset and equipment recoverability depends on forecasted performance - Stock-based compensation and public company costs affect operating expense --- *Last updated: 2026-04-29T05:11:49.216491+00:00*